SCHEMBL1339526

SCHEMBL1339526

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4coc(COC(=O)C(C)(C)C)n4)ccc3n(C)c21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 14/20 0.36
▸ CNR2 P34972 13/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ GABRA1 P14867 3/20 0.33
▸ ADRA2C P18825 2/20 0.33
▸ SLC6A3 Q01959 2/20 0.33
▸ EGFR P00533 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ MAPK3 P27361 1/20 0.33
▸ OPRL1 P41146 1/20 0.33
▸ SLC18A2 Q05940 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ TMEM97 Q5BJF2 1/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.33
▸ ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339189 0.86 GABRA1 (0.41) CNR1CNR2TDP1GABRA1ADRA2C
SCHEMBL1339478 0.86 CNR1 (0.39) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1337230 0.85 NPC1 (0.35) CNR1CNR2NPC1RAB9ATDP1
SCHEMBL1336992 0.85 RAB9A (0.55) CNR1CNR2NPC1RAB9ATDP1
SCHEMBL1336863 0.81 KDM4E (0.39) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3250019 0.80 KDM4E (0.39) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339390 0.80 CNR1 (0.40) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339112 0.78 RAB9A (0.61) NPC1RAB9ATDP1L3MBTL1KDM4E
SCHEMBL1339396 0.77 RAB9A (0.51) CNR1CNR2NPC1RAB9ATDP1
SCHEMBL1339024 0.76 CNR1 (0.36) CNR1CNR2GABRA1ADRA2CSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 CNR1 262/4885CNR2 299/4885NPC1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback